**18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation**

Amanda F. Cashen1,2, Farrokh Dehdashti1,3, Jingqin Luo1,4, Andrew Homb3, Barry A. Siegel1,3, and Nancy L. Bartlett1,2

1Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri; 2Division of Oncology, Washington University School of Medicine, St. Louis, Missouri; 3Division of Nuclear Medicine, Washington University School of Medicine, St. Louis, Missouri; and 4Division of Biostatistics, Washington University School of Medicine, St. Louis, Missouri

PET using 18F-FDG has prognostic value when performed at the completion of initial chemotherapy in patients with diffuse large B-cell lymphoma (DLBCL). 18F-FDG PET may also be predictive of outcome when performed during the treatment course of DLBCL, but robust prospective studies and standardization of 18F-FDG PET interpretation in this setting are lacking. **Methods:** In this prospective study, patients with advanced-stage DLBCL were treated with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy, and 18F-FDG PET/CT was performed after cycle 2 or 3 and at the end of therapy. The 18F-FDG PET/CT scans were interpreted according to the International Harmonization Project for Response Criteria in Lymphoma, and the maximum standardized uptake value (SUV) of the most 18F-FDG-avid lesions was recorded. **Results:** Fifty patients were enrolled, and all underwent interim 18F-FDG PET/CT. At a median follow-up of 33.9 mo, the positive predictive value (PPV) of interim 18F-FDG PET/CT for relapse or progression was 42%, and the negative predictive value (NPV) was 77%. Interim 18F-FDG PET/CT was significantly associated with event-free survival (P = 0.017) and with progression-free survival (P = 0.04) but not with overall survival (P = 0.08). End-of-therapy 18F-FDG PET/CT had high PPV and NPV (71% and 80%, respectively) and was significantly associated with event-free survival, progression-free survival, and overall survival (P < 0.001). SUV measurements did not discriminate patients who relapsed or progressed from those who remained in remission. **Conclusion:** When performed after 2 cycles of immunochemotherapy and interpreted according to International Harmonization Project criteria, early response assessment with PET/CT has a high NPV but low PPV in patients with advanced-stage DLBCL. Prospective trials are required to validate different criteria for the interpretation of interim 18F-FDG PET/CT and establish the role of interim 18F-FDG PET/CT in the management of patients with DLBCL.

**Key Words:** 18F-FDG; PET; PET/CT; non-Hodgkin lymphoma; prognosis

DOI: 10.2967/jnumed.110.082586

PET with 18F-FDG is a reliable and widely used imaging modality for the staging and response assessment of aggressive non-Hodgkin lymphomas (NHLs), including diffuse large B-cell lymphoma (DLBCL). For response assessment, 18F-FDG PET adds valuable information to that obtained with CT, because, unlike CT, 18F-FDG PET often can differentiate viable tumor from posttreatment fibrosis or necrosis. Two meta-analyses have supported the important prognostic value of 18F-FDG PET performed at the completion of therapy for aggressive NHL (1,2). The most recent lymphoma response criteria incorporate 18F-FDG PET into the definition of response (3), using standards established by the International Harmonization Project for Response Criteria in Lymphoma (IHP) to interpret end-of-therapy 18F-FDG PET scans as positive or negative (4).

The value of 18F-FDG PET performed during the course of induction chemotherapy for DLBCL is less well established. Interim 18F-FDG PET may reflect the lymphoma’s chemosensitivity and predict whether the malignant cells will be completely eradicated by the end-of-chemotherapy course. This principle is supported by multiple studies that have reported high positive and negative predictive values (PPVs and NPVs, respectively) of 18F-FDG PET performed after 2–4 cycles of therapy for lymphoma (5–9). Unfortunately, these studies are hampered by heterogeneity with respect to lymphoma subtypes, chemotherapy regimens, timing of interim PET, and the criteria used to interpret the scans.

Here we report the results of a prospective study of patients with newly diagnosed, advanced-stage DLBCL treated with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy, all of whom underwent 18F-FDG PET/CT after 2–3 cycles of chemotherapy. In an effort to standardize the interpretation of interim 18F-FDG PET scans, we evaluated the predictive value of interim 18F-FDG PET/CT based on the IHP criteria established for end-of-treatment PET.

**MATERIALS AND METHODS**

This prospective single-arm study enrolled adult patients with histologically proven, advanced-stage, untreated DLBCL. Initially,
the primary objective of the study was to correlate gene polymorphisms that responded to R-CHOP with response defined by \(^{18}\text{F}-\text{FDG PET/CT}\) after 2 cycles of therapy. When the IHP criteria were established in 2007, we reviewed the \(^{18}\text{F}-\text{FDG PET/CT}\) scans in our data set, with the aim of correlating the interim \(^{18}\text{F}-\text{FDG PET/CT}\) results, interpreted according to IHP criteria, with clinical outcomes.

Inclusion criteria were diagnosis of de novo, untreated DLCBL; Ann Arbor stage III–IV; and age 18 y or older. Patients were excluded if they had central nervous system involvement, had HIV infection, or were to receive radiation therapy as part of the initial treatment plan. The study was approved by the institutional review board, and all patients gave written informed consent.

Patients were treated with standard-dose R-CHOP at 3-wk intervals for 6 cycles (10). The protocol called for \(^{18}\text{F}-\text{FDG PET/CT}\) to be performed at 3 wk after cycle 2 and at the end of treatment. Therapy was not changed on the basis of interim \(^{18}\text{F}-\text{FDG PET/CT}\) results.

\(^{18}\text{F}-\text{FDG PET/CT} and Analysis

The interim and end-of-therapy\(^ {18}\text{F}-\text{FDG PET/CT}\) scans were obtained at our institution with a Biograph Duo or a Biograph-40 (Siemens) scanner, following our standard clinical protocol, which is consistent with the recommendations of the IHP Imaging Subcommittee (4). The fasting glucose was required to be less than 200 mg/dL (mean, 111 mg/dL; range, 84–188 mg/dL) immediately before injection of 370–555 MBq (10–15 mCi) of \(^{18}\text{F}-\text{FDG}\). After approximately 1 h, a spiral CT scan (typically 95–111 effective mAs, 130 kVp, and 5-mm slice thickness), with oral—but not intravenous—contrast agent administration, was acquired, followed by pelvis–to–skull base emission images. The PET emission images were corrected for measured attenuation and reconstructed using an ordered-subset expectation maximization iterative algorithm per the manufacturer’s instructions.

All PET/CT images were interpreted in standard clinical fashion. After all patients had been treated, the \(^{18}\text{F}-\text{FDG PET/CT}\) scans were retrospectively reviewed by 2 nuclear radiologists and designated positive or negative according to the following consensus response criteria of the IHP (4):

- Focal or diffuse \(^{18}\text{F}-\text{FDG}\) uptake above background
- In a mass 2 cm or larger, mild and diffusely increased \(^{18}\text{F}-\text{FDG}\) uptake that is greater than that in mediastinal blood-pool structures
- Any increased uptake in a mass smaller than 2 cm
- New lung nodules 1.5 cm or larger, with uptake less than that in the mediastinal blood pool
- Hepatic or splenic lesions 1.5 cm or larger, if uptake is more than uptake in liver or spleen; or diffusely increased splenic uptake
- Clearly increased focal or multifocal bone involvement

The radiologists were unaware of the clinical outcomes. To explore whether quantification of \(^{18}\text{F}-\text{FDG}\) uptake in residual masses would allow discrimination of patients who do and do not relapse, the maximum standardized uptake value (SUVMax) was measured at residual sites of disease on interim scans that were positive by IHP criteria. Whenever available, baseline \(^{18}\text{F}-\text{FDG PET/CT}\) scans were used to identify initial sites of disease. In patients with multiple lesions, the standardized uptake values (SUVs) of the most \(^{18}\text{F}-\text{FDG}\)–avid lesions (≤7) were determined, and the average value correlated with response. The SUVMax of the lesions was compared with the average SUVs of the aortic blood pool, as determined by drawing a 1-cm oval region of interest in the aortic arch, and the average SUV of the liver, as determined by drawing a sphere 3 × 3 cm region of interest in the mid liver.

Statistical Analysis

The objective of this analysis was to estimate the predictive value of interim \(^{18}\text{F}-\text{FDG PET/CT}\) in patients with advanced-stage DLBCL treated with R-CHOP, using the IHP consensus response criteria for interpretation of \(^{18}\text{F}-\text{FDG PET/CT}\) scans. Our sample size of 50 patients provides 95% power to detect a 2-y progression-free survival (PFS) of 30% for positive interim PET versus 85% for negative interim PET (11). Sensitivity, specificity, PPV, NPV, and positive and negative likelihood ratios, with 95% confidence interval, for predicting disease progression were calculated for interim and end-of-therapy \(^{18}\text{F}-\text{FDG PET/CT}\) scans. Overall survival (OS), PFS, and event-free survival (EFS) were separately defined to be the time interval from enrollment in the study to date of death, to date of relapse, and to the earlier date of an event (death, relapse, or next therapy), respectively. Kaplan–Meier curves were generated for the time-to-event outcomes according to interim or final \(^{18}\text{F}-\text{FDG PET/CT}\) result (positive vs. negative). P values from log-rank tests were calculated, and survival probabilities at year 2 were estimated. SUVs were compared between 2 groups using the Wilcoxon rank sum test. All tests were 2-sided, and the significance level was set at 0.05. All analyses were performed in R 2.7.1 (http://cran.r-project.org).

RESULTS

Patient Characteristics

Fifty-two patients were enrolled between March 2005 and May 2008 (mean age, 58 y; range, 29–80 y). Two patients were excluded for histology other than DLBCL (Burkitt’s and mantle cell lymphoma), and they are not included in the analysis. All patients had stage III or IV disease, and 68% had International Prognostic Index scores indicating high–intermediate risk or high risk (Table 1) (12).

| Table 1 |

Patient Outcomes

Forty-four patients (88%) completed 6 cycles of R-CHOP. Three patients stopped therapy after 4 (n = 2) or 5 (n = 1) cycles because of toxicity, and 3 patients had progressive disease after 2, 4, and 5 cycles of R-CHOP. Interim \(^{18}\text{F}-\text{FDG PET/CT}\) was performed at 3 wk after cycle 2 in 47 patients (94%) but was delayed until the end of cycle 3 in the remaining 3 patients because of scheduling errors. Forty-two patients (84%) also underwent end-of-therapy \(^{18}\text{F}-\text{FDG PET/CT}\) after 6 (n = 41) or 5 (n = 1) cycles of R-CHOP. Eight patients did not undergo end-of-therapy \(^{18}\text{F}-\text{FDG PET/CT}\) because they stopped treatment early for toxicity (n = 2) or progressive disease (n = 3) or because only a CT scan was obtained after cycle 6 (n = 3). No patients were treated with radiation or underwent biopsy of a residual \(^{18}\text{F}-\text{FDG}\)–avid site. Baseline \(^{18}\text{F}-\text{FDG PET}\) was not a study requirement and was performed in only 29 patients (58%). The 2-y EFS and OS of the entire study
population were 74% (95% confidence interval [CI], 63%–87%) and 75% (95% CI, 69%–90%), respectively (Fig. 1).

Thirteen patients died from progressive disease (n = 8), infection (n = 3), heart failure (n = 1), or complications of allogeneic stem cell transplantation (n = 1). Median follow-up for all surviving patients was 33.9 mo (range, 16–44 mo).

Predictive Value of \(^{18}\)F-FDG PET/CT Using IHP Criteria

On the basis of the IHP criteria, 24 patients, 10 of whom relapsed or progressed, had a positive interim \(^{18}\)F-FDG PET/CT scan result (PPV, 42%; 95% CI, 22%–61%; Fig. 2A). Among these 10 patients, 1 patient had progressive disease in the central nervous system after cycle 4 of R-CHOP, and 2 patients had obvious disease progression on the end-of-therapy \(^{18}\)F-FDG PET/CT scan. Another 7 patients with positive interim \(^{18}\)F-FDG PET/CT scan results relapsed at 3, 9, 12, 24, 26, 28, and 29 mo after completion of R-CHOP. In 6 of these 7 patients, relapse occurred in the sites of residual \(^{18}\)F-FDG uptake. An additional patient had residual intense uptake in a mediastinal mass after both cycle 2 and cycle 6 of R-CHOP and went on to salvage chemotherapy, autologous stem cell transplantation (ASCT), and mediastinal radiation therapy, with no subsequent disease progression. Two of the 10 patients who relapsed after a positive interim \(^{18}\)F-FDG PET/CT scan result are in a second complete remission 10 and 24 mo after ASCT.

Twenty-six patients, 6 of whom relapsed or progressed, had a negative interim \(^{18}\)F-FDG PET/CT scan result (NPV, 42%; 95% CI, 22%–61%; Fig. 2A). Among these 10 patients, 1 patient had progressive disease in the central nervous system after cycle 4 of R-CHOP, and 2 patients had obvious disease progression on the end-of-therapy \(^{18}\)F-FDG PET/CT scan. Another 7 patients with positive interim \(^{18}\)F-FDG PET/CT scan results relapsed at 3, 9, 12, 24, 26, 28, and 29 mo after completion of R-CHOP. In 6 of these 7 patients, relapse occurred in the sites of residual \(^{18}\)F-FDG uptake. An additional patient had residual intense uptake in a mediastinal mass after both cycle 2 and cycle 6 of R-CHOP and went on to salvage chemotherapy, autologous stem cell transplantation (ASCT), and mediastinal radiation therapy, with no subsequent disease progression. Two of the 10 patients who relapsed after a positive interim \(^{18}\)F-FDG PET/CT scan result are in a second complete remission 10 and 24 mo after ASCT.

Among the 42 patients who underwent \(^{18}\)F-FDG PET/CT at the end of therapy, 7 (17%) had a positive scan result and 35 (83%) had a negative scan result by IHP criteria. The PPV and NPV of end-of-therapy \(^{18}\)F-FDG PET/CT were 71% (95% CI, 30%–95%) and 80% (95% CI, 63%–91%), respectively (positive likelihood ratio, 6.25, and 95% CI, 1.40–27.9; negative likelihood ratio, 0.63, and 95% CI, 0.39–1.01; details of patient outcomes are provided in Fig. 2B). Among the 21 patients who had a positive interim PET scan result and an end-of-therapy PET scan, 7 continued to have a positive PET scan result at the end of therapy and 14 had converted to a negative PET scan result. All patients with a negative interim PET scan result also had a

![FIGURE 1. OS (A) and PFS (B) for study population, with 95% CIs.](image)

### TABLE 1
Characteristics of Patients (n = 50)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Number of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>B symptoms present</td>
<td>13 (26%)</td>
</tr>
<tr>
<td>Elevated lactate dehydrogenase</td>
<td>33 (66%)</td>
</tr>
<tr>
<td>Stage</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>15 (30%)</td>
</tr>
<tr>
<td>IV</td>
<td>35 (70%)</td>
</tr>
<tr>
<td>International Prognostic Index</td>
<td></td>
</tr>
<tr>
<td>Low (0–1)</td>
<td>7 (14%)</td>
</tr>
<tr>
<td>Low–Intermediate (2)</td>
<td>9 (18%)</td>
</tr>
<tr>
<td>High–Intermediate (3)</td>
<td>18 (36%)</td>
</tr>
<tr>
<td>High (4–5)</td>
<td>16 (32%)</td>
</tr>
<tr>
<td>Cycles of R-CHOP</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>1 (2%)</td>
</tr>
<tr>
<td>4</td>
<td>3 (6%)</td>
</tr>
<tr>
<td>5</td>
<td>2 (4%)</td>
</tr>
<tr>
<td>6</td>
<td>44 (88%)</td>
</tr>
</tbody>
</table>

![FIGURE 2. OS (A) and PFS (B) for study population, with 95% CIs.](image)
negative end-of-therapy PET scan result, if that scan was performed.

Survival According to 18F-FDG PET/CT Results

Although a trend was observed, there was not a statistically significant difference in OS between patients with a positive or negative interim 18F-FDG PET/CT scan result \((P = 0.08, \text{Fig. 3A})\). PFS and EFS probability were lower in patients with a positive interim 18F-FDG PET/CT scan result \((P = 0.04 \text{ and } 0.031, \text{respectively, Fig. 3B})\), with a 2-y EFS probability of 63% (95% CI, 46%–85%) in patients with a positive interim scan result versus 85% (95% CI, 72%–100%) in patients with a negative interim 18F-FDG PET/CT scan result. OS, PFS, and EFS were significantly associated with the end-of-therapy 18F-FDG PET/CT results \((P < 0.00001 \text{ for all 3 measures; Figs. 3C and 3D})\).

SUVs of Positive Interim 18F-FDG PET/CT Studies

Because of technical limitations, SUVs could not be measured on 1 of 24 positive interim 18F-FDG PET/CT studies, from a patient who relapsed. In the other patients who relapsed or progressed, the average \(SUV_{max}\) of the most 18F-FDG–avid disease site on the interim scan was 5.2 (range, 1.2–13.8), compared with 4.8 (range, 1.7–14.0) in the patients who remained in remission \((P = 0.56)\). The average SUVs of the most 18F-FDG–avid sites \((\leq 7)\) on the interim scans also were not statistically different in patients who relapsed or progressed and those who remained in remission \((3.2 \text{ vs. } 3.0, \text{respectively, } P = 0.45)\). SUVs of 18F-FDG–avid disease sites were also analyzed as a ratio of lesion SUV to blood pool or liver SUV. For reference, the mean SUVs of the blood pool and liver in the interim 18F-FDG PET/CT studies were 1.6 (range, 0.88–2.5) and 2.4 (range, 1.7–3.6), respectively. The mean ratio of \(SUV_{max}\) and SUV of the blood pool was 3.3 (range, 1.2–10.5) in patients who relapsed or progressed, compared with 3.0 (range, 1.1–9.0) in those who remained in remission \((P \geq 0.5)\). Similarly, there was no statistically significant difference between the 2 outcome groups when \(SUV_{max}\) was referenced to liver SUV or when the average SUVs of the most 18F-FDG–avid sites were referenced to the blood pool or liver SUV \((all P \geq 0.5)\).

DISCUSSION

In this prospective study of patients with advanced-stage DLBCL treated with standard R-CHOP immunotherapy, interim 18F-FDG PET/CT had a low positive-predictive value for relapse (42%) and did not have a statistically significant association with OS, although there was an association with PFS and EFS. These results are in contrast to previous studies, which have a reported PPV of 71%–100% for interim 18F-FDG PET in aggressive NHL \((5,8,11,13)\), and a recent meta-analysis, which found a sensitivity of 0.78 and specificity of 0.87 for
interim 18F-FDG PET in DLBCL (14). However, these studies have important limitations. For instance, the meta-analysis included 311 DLBCL patients from 6 studies who had stage I–IV disease and were treated with a variety of regimens, with and without rituximab, radiation, and even consolidative stem cell transplantation. Median follow-up ranged from 15 to 36 mo, and 18F-FDG PET was performed after 2, 3, or 4 cycles of therapy. In fact, the authors of the meta-analysis could not draw a conclusion about the value of interim 18F-FDG PET in DLBCL because of the heterogeneity of the available studies.

Although limited by small sample size, our study enrolled a homogeneous population of advanced-stage DLBCL patients who received standard immunochemistry and had consistent timing and interpretation of the interim 18F-FDG PET/CT scans. One weakness of our study is that the treating physician was aware of the interim 18F-FDG PET/CT results. However, in no patient was treatment changed on the basis of the interim 18F-FDG PET/CT results. Another weakness is that baseline 18F-FDG PET was not performed on all patients. This deficiency does not affect our application of the IHP criteria to the interim 18F-FDG PET/CT scans, but it does limit our ability to explore the predictive value of the change in SUV and it may have impaired the radiologists’ ability to interpret the interim scans. Also, the 18F-FDG PET/CT scans were not obtained using a strict research protocol, but rather reflect the variations in technique, particularly scan timing, that occur in the course of routine clinical practice.

The important potential of interim 18F-FDG PET in aggressive lymphomas is to distinguish prognostic groups whose outcomes are sufficiently divergent to warrant a change in therapy. Our results demonstrate that the IHP criteria applied to interim scans in DLBCL do not accomplish this goal. Although patients with a positive interim 18F-FDG PET/CT scan did have inferior EFS, their EFS probability at 2 y was still 63%. On the other hand, we found that the NPV of interim 18F-FDG PET/CT interpreted by IHP criteria was high (77%), consistent with previous reports.

Application of other criteria may improve the prognostic value of interim 18F-FDG PET. For instance, Mikhaeel et al. have separated patients with minimal residual uptake from those with a more obviously positive interim 18F-FDG PET scan (8,15). Although we did not formally apply these criteria in our study, it is unlikely a minimal residual uptake category would improve the predictive value of our data set, given that the mean, median, and range of SUVs were essentially identical in patients who did and did not relapse after a positive interim scan. In response to criticism that minimal residual uptake is too subjective, a 5-point scoring system for 18F-FDG PET interpretation was developed at

FIGURE 3. (A) OS according to interim 18F-FDG PET/CT results. (B) PFS according to interim 18F-FDG PET/CT results. (C) OS according to end-of-therapy 18F-FDG PET/CT results. (D) PFS according to end-of-therapy 18F-FDG PET/CT results.
Guy’s and St. Thomas’ Hospital, London, and is being applied in several European studies (16, 17). This scoring system has the potential to provide reproducible grades of positive and negative $^{18}$F-FDG PET results, but it requires validation in NHL. A final method for interpretation of interim $^{18}$F-FDG PET scans is a semiquantitative approach based on relative reduction in SUV. Lin et al. found that an SUV-based assessment improved the PPV of interim $^{18}$F-FDG PET in DLBCL over that achieved with visual assessment (18). However, it may prove difficult to reproduce any SUV-based criteria reliably when scan conditions are not controlled in a research setting.

Several recent reports support our findings and underline the importance of the criteria used to interpret interim $^{18}$F-FDG PET scans in DLBCL. Han et al. used criteria similar to the IHP criteria in a retrospective study of DLBCL and mantle cell lymphoma patients treated with rituximab and chemotherapy (19). They reported a PPV and NPV for interim $^{18}$F-FDG PET of 33% and 68%, respectively, similar to our results. In a preliminary report, Pregno et al. used the consensus response criteria to interpret $^{18}$F-FDG PET scans obtained for DLBCL patients after 2–4 cycles of R-CHOP (20). With relatively early follow-up, interim $^{18}$F-FDG PET did not correlate with PFS ($P = 0.198$). On the other hand, Safar et al. used a more stringent definition of positive interim $^{18}$F-FDG PET in their prospective study of DLBCL patients treated with rituximab and chemotherapy (21). They scored scans with minimal residual uptake as negative. In their initial analysis, they report a 5-y PFS of 81% for patients with a negative $^{18}$F-FDG PET scan result after cycle 2 versus 47% for those with a positive scan result ($P < 0.0001$). In another preliminary report, Micaleff et al. found no correlation between 2-y EFS and PET performed after 2 cycles of epratuzumab combined with R-CHOP in patients with DLBCL (22). Similar to our findings, 2-y EFS was 60% in the patients with a positive interim PET scan, although the criteria they used for PET interpretation are not defined.

Our data support the recommendation that interim $^{18}$F-FDG PET should be performed only in the context of clinical trials and should not yet be used to make treatment decisions in routine clinical practice. Ongoing clinical trials that alter therapy on the basis of the interim $^{18}$F-FDG PET may be difficult to interpret, as it is not clear that a positive $^{18}$F-FDG PET scan result defines a poor-risk group of patients in whom a change in therapy is warranted. For instance, Kasamon et al. used a risk-adapted approach to treat 59 patients with aggressive lymphoma, 56 of whom had DLBCL treated with R-CHOP (23). Patients who had a positive $^{18}$F-FDG PET scan result after cycle 2 (using criteria similar to IHP criteria) had their treatment changed to salvage chemotherapy, followed by ASCT. More than half of the DLBCL patients had a positive interim $^{18}$F-FDG PET scan result. The 2-y EFS for those who underwent ASCT was 74%, compared with 88% for those who had a negative interim $^{18}$F-FDG PET scan result and had completed R-CHOP. In a study by Moscowitz et al., $^{18}$F-FDG PET was performed in 97 patients with DLBCL after 4 cycles of dose-dense R-CHOP, and treatment was changed to ifosfamide–carboplatin–etoposide in patients who had a positive scan result (24). PFS was 79%, with no difference in outcome based on the interim $^{18}$F-FDG PET scan result. Of note, in 33 of 38 patients, biopsy of a positive site on the interim scan was negative for residual lymphoma. These outcomes with intensification of therapy for positive interim $^{18}$F-FDG PET are difficult to interpret in light of our results, as well as those of Han et al. (19) and Pregno et al. (20), who found that fewer than half of patients with a positive interim $^{18}$F-FDG PET scan result will relapse after a standard course of immunotherapy. If our results are supported by larger patient cohorts, intensification of therapy based on interim $^{18}$F-FDG PET would lead to overtreatment of a substantial portion of patients.

A recent report from Horning et al. (25) sounds an additional note of caution for the use of interim $^{18}$F-FDG PET in clinical decision making. A panel of 3 expert nuclear medicine physicians reviewed the $^{18}$F-FDG PET scans collected after 3 cycles of R-CHOP in the Eastern Cooperative Oncology Group E3404 study. Agreement among the 3 reviewers was only 68% and 71% when they interpreted the interim scans according to modified IHP criteria and the London criteria, respectively. Given that reporting of interim $^{18}$F-FDG PET can vary significantly even in a controlled research setting, further standardization of $^{18}$F-FDG PET interpretation is clearly needed. To that end, an international consensus group is validating interim PET assessment in DLBCL based either on a 5-point visual scale or on SUV analysis (26).

**CONCLUSION**

Mid-treatment $^{18}$F-FDG PET may prove useful as a predictive factor for patients with DLBCL undergoing induction chemotherapy, but the appropriate criteria for interpretation and subsequent modifications in therapy are yet to be established. Our results do not support use of the IHP criteria for interpretation of $^{18}$F-FDG PET/CT scans obtained after cycle 2 of immunochemotherapy. Future studies should consider use of different interpretive criteria or delay of interim $^{18}$F-FDG PET to later in the treatment course. On the other hand, our results do confirm the strong predictive value of $^{18}$F-FDG PET performed at the end of therapy. Outside a clinical trial, $^{18}$F-FDG PET/CT should be used only to guide end-of-therapy decisions, a setting in which it has established prognostic value.

**ACKNOWLEDGMENTS**

This study was supported by a grant from the Barnes-Jewish Hospital Foundation.

**REFERENCES**

1. Zijlstra J, Lindauer-van der Werf G, Hoekstra O, Hooft L, Riphagen I, Huijgens P. $^{18}$F-fluoro-deoxyglucose positron emission tomography for post-treatment...

12. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A pre-

10. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab com-


4. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomo-


2. Terasawa T, Nihashi T, Hotta T, Nagai H. 18F-FDG PET for posttherapy assess-

1. The Journal of Nuclear Medicine • Vol. 52 • No. 3 • March 2011


22. Micallef IN, Maurer MJ, Witzig TE, et al. PET scan results of NCCTG N0489:


19. Han HS, Escalon MP, Hsiao B, Serafini A, Lossos IS. High incidence of false-


17. Mikhaeel NG. Interim fluorodeoxyglucose positron emission tomography for

16. Radford J, O’Doherty M, Barrington S, et al. Results of the 2nd planned interim

15. Mikhaeel NG, Timothy AR, O’Doherty MJ, Hain S, Maisey MN. 18-FDG-PET


12. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A pre-

10. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab com-


4. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomo-


2. Terasawa T, Nihashi T, Hotta T, Nagai H. 18F-FDG PET for posttherapy assess-

1. The Journal of Nuclear Medicine • Vol. 52 • No. 3 • March 2011


22. Micallef IN, Maurer MJ, Witzig TE, et al. PET scan results of NCCTG N0489:


19. Han HS, Escalon MP, Hsiao B, Serafini A, Lossos IS. High incidence of false-


17. Mikhaeel NG. Interim fluorodeoxyglucose positron emission tomography for

16. Radford J, O’Doherty M, Barrington S, et al. Results of the 2nd planned interim

15. Mikhaeel NG, Timothy AR, O’Doherty MJ, Hain S, Maisey MN. 18-FDG-PET


12. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A pre-

10. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab com-


4. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomo-


2. Terasawa T, Nihashi T, Hotta T, Nagai H. 18F-FDG PET for posttherapy assess-

1. The Journal of Nuclear Medicine • Vol. 52 • No. 3 • March 2011


22. Micallef IN, Maurer MJ, Witzig TE, et al. PET scan results of NCCTG N0489:


19. Han HS, Escalon MP, Hsiao B, Serafini A, Lossos IS. High incidence of false-


17. Mikhaeel NG. Interim fluorodeoxyglucose positron emission tomography for

16. Radford J, O’Doherty M, Barrington S, et al. Results of the 2nd planned interim

15. Mikhaeel NG, Timothy AR, O’Doherty MJ, Hain S, Maisey MN. 18-FDG-PET


12. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A pre-

10. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab com-


4. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomo-


2. Terasawa T, Nihashi T, Hotta T, Nagai H. 18F-FDG PET for posttherapy assess-

1. The Journal of Nuclear Medicine • Vol. 52 • No. 3 • March 2011


